Navigation Links
Pharmatek Laboratories Announces Acquisition of the First Xcelodose(R) 600S System on the West Coast
Date:10/2/2009

SAN DIEGO, Oct. 2 /PRNewswire/ -- Pharmatek Laboratories, Inc., a premier contract development and manufacturing organization supporting the pharmaceutical industry, announced that it is the first CRO on the West Coast to acquire the Xcelodose system, enhancing the company's preclinical and early phase clinical GMP supply capabilities.

"Pharmatek is always looking for ways to move our customers' drug candidates into the clinic more efficiently without compromising quality," said Jeffrey Bibbs, Ph.D., Chief Scientific Officer of Pharmatek Laboratories. "For powder-in-capsule (PIC) applications, the Xcelodose can drastically decrease time to clinic while also lowering the cost of drug product for first-in-human trials."

The Xcelodose, manufactured by Capsugel, a division of Pfizer, is a precision powder micro-doser and automated encapsulator that has the ability to fill formulations or active pharmaceutical ingredient (API) directly into capsules with a remarkable level of accuracy. The Xcelodose can measure to levels as low as 100 micrograms and can dispense into capsules from size 00 to 4. Dosing directly into capsules can reduce the amount of API required. Additionally, the unit reduces overall development time by simplifying analytical and stability protocols.

Pharmatek Laboratories will install the Xcelodose unit in its solid dose manufacturing facility located in San Diego, California. The unit is expected to be validated by mid-October 2009. The company is currently scheduling Xcelodose manufacturing productions for November and December, 2009.

About Pharmatek Laboratories, Inc.

Pharmatek Laboratories, Inc. is a premier pharmaceutical chemistry development company providing full-service pharmaceutical chemistry product development for the pharmaceutical industry. Pharmatek focuses on bringing client compounds from discovery to the clinic with services that include compound selection, analytical development, preformulation testing, formulation development, GMP manufacturing, stability storage and testing, and cytotoxic and high-potency development.

Statements contained in this media release which are not historical facts may constitute forward-looking statements. All forward-looking statements are subject to risks and uncertainties which could cause actual results to differ from those projected including sales forecasts and strategic expansion. The trademarks Pharmatek, Pharmatek Laboratories, Inc., Hot Rod Chemistry, Pharmatek Formulation Screening, Pharmatek University and PTEK U are all property of Pharmatek Laboratories, Inc. Additional information about Pharmatek Laboratories may be obtained at the website http://www.pharmatek.com or by calling 858-805-6383.

    Company Contact:
    Ryan Lane, Marketing Coordinator
    Pharmatek Laboratories, Inc.
    (858) 805-6383 x284
    rlane@pharmatek.com

SOURCE Pharmatek Laboratories, Inc.


'/>"/>
SOURCE Pharmatek Laboratories, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Pharmateks Highly-Potent and Cytotoxic (HP/C) Facility Positions It as Industry Leader in Development and Manufacturing of HP/C Compounds
2. Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM)
3. Forest Laboratories, Inc. and Gedeon Richter Announce Results of Phase II-B Study for RGH-188 as a Treatment for Schizophrenia
4. Forest Laboratories, Inc. Announces Positive Results of LEXAPRO(R) Phase III Study in Adolescents With Major Depression
5. Romark Laboratories Raises $18 Million in Institutional Financing
6. Microbia and Forest Laboratories Announce Preliminary Results of Linaclotide Phase 2b Studies
7. Romark Laboratories Initiates Phase II Study of Nitazoxanide in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1
8. Northfield Laboratories Inc. Presentation at FDA/NIH Workshop on Hemoglobin-Based Oxygen Carriers
9. Ironwood Pharmaceuticals and Forest Laboratories Announce Presentation of Linaclotide Phase 2b Chronic Constipation Study Results
10. Romark Laboratories Completes Enrollment in U.S. Phase II Study of Nitazoxanide for Chronic Hepatitis C Genotype 1 Non-Responders
11. Forest Laboratories Announces Positive Results from Phase III Clinical Studies of Ceftaroline for the Treatment of Complicated Skin and Skin Structure Infections
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... February 12, 2016 ... titled Chronic Inflammation Global Clinical Trials Review, H2, ... the global clinical trials landscape along with top ... Region, Country (G7 & E7), Trial Status, Trial ... reviews top companies involved and enlists all trials ...
(Date:2/11/2016)... (NasdaqCM: PDEX) today announced financial results for its fiscal 2016 ... its Quarterly Report on Form 10-Q for the second quarter ... today. --> --> Quarter ... --> Net sales for the three months ended December ... from $2.8 million for the three months ended December 31, ...
(Date:2/11/2016)... -- Governor Andrew M. Cuomo today announced a major expansion ... Western New York . This announcement, made ... includes a major expansion of Athenex,s North American headquarters ... , as well as the creation of a state-of-the-art, ... . The combined projects are expected to yield ...
Breaking Medicine Technology:
(Date:2/12/2016)... (PRWEB) , ... February 12, 2016 , ... Healthcare careers ... the five most searched jobs via the website of healthcare staffing leader Aureus Medical ... travel nurse jobs , travel therapy positions and in travel and ...
(Date:2/12/2016)... ... February 12, 2016 , ... The aging population ... of long term care. With that, says Patrick Loughney, president of Longtree ... roles in long term care environments. His company, which offers prep courses and ...
(Date:2/12/2016)... ... ... Basketball is a game for everyone, not just those who can hear! ... translation is featured in the top right of the screen. Every technique that is ... sign language translator to teach kids the game and how to be as active ...
(Date:2/12/2016)... ... February 12, 2016 , ... With the exception of restorative dentistry, to date there has been ... the recent approval by the FDA, there is a now a new protocol in stopping ... is very simple and quick to apply. The application is as simple as drying ...
(Date:2/11/2016)... ... ... Fitbody Personal Training offers outdoor training classes which includes an equestrian boot camp ... Located in Phoenixville, PA, the classes are structured as fun and friendly. , Fitbody ... to lose weight and tone up. This class offers a balance of exercises which ...
Breaking Medicine News(10 mins):